A mutation linked to cisplatin resistance in hypopharyngeal squamous cell carcinoma
The 2 cancer-care developments that matter from the last 3 days, strongest evidence first.
- A mutation linked to cisplatin resistance in hypopharyngeal squamous cell carcinoma
- Study finds protein-form switches in acute myeloid leukemia
A mutation linked to cisplatin resistance in hypopharyngeal squamous cell carcinoma
Researchers analyzed tissue from nine people with hypopharyngeal squamous cell carcinoma; six had new mutations when their cancer progressed. Lab and tumor model tests found one mutation promoted cisplatin resistance.
“Our study identifies ENPP1 mutation as one of the key genetic drivers of recurrence, mediating both chemotherapy resistance and immunomodulation.”
What this means. Lab or animal research on cancer. Not yet tested as a treatment in people; many lab results never reach patients.
British Journal of Cancer, 3 Oct 2026 · Translational research (lab work plus patient samples)Study finds protein-form switches in acute myeloid leukemia
Researchers compared cancer and normal tissue samples, including from people with acute myeloid leukemia, and found changes in the most common protein forms. They verified 12.1% of the identified changes using protein data.
“This study identifies cMDTs that may serve as candidate biomarkers in melanoma, ovarian cancer, and acute myeloid leukaemia, with the potential to improve cancer diagnosis and support clinical decision-making.”
What this means. Based on data or samples from people with acute myeloid leukaemia, a blood cancer. It is not a treatment trial.
British Journal of Cancer, 3 Oct 2026 · Human observational studyDeals and stopped trials
- FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancerascopost.com
- FDA Approves First-Line Pirtobrutinib for CLL-SLLascopost.com
- A Study of PTX-9908 Injection for Non-resectable hepatocellular carcinoma With TACEWithdrawn · Phase I/II · TCM Biotech International Corp. · Reason given: Due to business considerations and challenges in participant recruitment, the Sponsor has decided to discontinue the study.
- Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeTerminated · Phase I · Bristol-Myers Squibb · Reason given: Inability to meet protocol objectives
India
- Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian CancerNew trial in India · Phase III · AstraZeneca
Worth watching
- Chemotherapy improves cancer vaccine responses in lab studiesIn lab studies, carboplatin plus paclitaxel improved cancer vaccine responses; patient samples from people with different cancers showed a rise in immune cells. Adding another drug further improved tumor control and survival in lab studies.
- A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trialPhase I, early-stage human trial, Nature Communications, 4 Oct 2026
- Targeting Distinct Cell Cycle Nodes Overcomes RAS Inhibitor ResistancePreclinical, laboratory or animal-stage, Cancer Research, 2 Oct 2026
- Gut microbiome features associated with PIK3CA-mutated colorectal cancer: A nationwide pan-cancer genomic and microbial profiling study (MONSTAR-SCREEN)Research finding, Scientific Reports, 4 Oct 2026